Estudos Randomizados
Estudo randomizado | Angioplastia pulmonar por balão vs. riociguat para tratamento de hipertensão pulmonar tromboembólica crônica não operável.
9 Ago, 2022 | 17:11hBalloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study – The Lancet Respiratory Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
NEW—Pulmonary vascular resistance reduction was more pronounced with balloon pulmonary angioplasty (BPA) than with riociguat, but treatment-related SAEs were more common with BPA
Read the RACE trial from Xavier Jaïs & colleagues https://t.co/h9r3Qe2mCb
— The Lancet Respiratory Medicine (@LancetRespirMed) August 2, 2022
Estudo randomizado | Valor terapêutico da biópsia de linfonodo sentinela em pacientes com melanoma.
5 Ago, 2022 | 17:21hTherapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (gratuito por tempo limitado)
Comentário convidado: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (gratuito por tempo limitado)
Estudo randomizado | Estimulação transcraniana por corrente contínua vs. tratamento simulado para tratamento de desatenção em adultos com transtorno de déficit de atenção/hiperatividade.
5 Ago, 2022 | 17:16hTranscranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial – JAMA Psychiatry (gratuito por tempo limitado)
Ver também: Visual Abstract
Estudo randomizado | Comparação da mudança para dose a cada 6 semanas de natalizumabe vs. continuar a dose a cada 4 semanas em pacientes com esclerose múltipla recorrente-remitente.
5 Ago, 2022 | 17:05hComparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial – The Lancet Neurology (link para o resumo – $ para o texto completo)
Comentário: Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy – Medscape (necessário cadastro gratuito)
Estudo randomizado | Fundoplicatura posterior total vs. parcial no reparo cirúrgico de hérnias paraesofágicas.
5 Ago, 2022 | 17:01h
Comentário no Twitter
Does wrap type affect #dysphagia #qol and #recurrence in paraoesophageal #hernia repair?#RCT n=70 Nissen vs Toupet
Partial wrap (Toupet) assoc w/reduced dysphagia, better qol. No diff recurrence rate.#some4surgery #surgicalresearch #some4ugihttps://t.co/8tIvryfqYJ pic.twitter.com/47AT1lLPH8— BJS Open (@BjsOpen) May 9, 2022
Estudo randomizado | Patiromer para tratamento de hiperpotassemia na insuficiência cardíaca com fração de ejeção reduzida.
5 Ago, 2022 | 16:27h
Comentário no Twitter
No one wants to add meds just so you can add more meds. BUT, adding patiromer in select patients with HFrEF so you can optimize GDMT sure is compelling… 🤔 https://t.co/79gSEwon4y
— ATRIUM Cardiology (@ATRIUMRx) July 29, 2022
Estudo randomizado | Segurança e eficácia da tirzepatida como adição à medicação anti-hiperglicêmia oral única em pacientes com diabetes tipo 2 no Japão.
4 Ago, 2022 | 14:09hSafety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Ver também (nota: a dose de dulaglutida usada neste estudo foi provavelmente subótima): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link para o resumo – $ para o texto completo)
Conteúdos relacionados:
Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link para o resumo – $ para o texto completo)
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link para o resumo – $ para o texto completo)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022
Estudo randomizado | Em pacientes sob risco de deficiência antitrombínica após cirurgia cardíaca, a suplementação antitrombínica pré-operatória não resultou em desfechos melhores.
4 Ago, 2022 | 13:58hA Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Antithrombin Supplementation in Patients at Risk for Antithrombin Deficiency After Cardiac Surgery – Anesthesia & Analgesia (link para o resumo – $ para o texto completo)
Estudo randomizado | Intervenção com metotrexato em pacientes com artralgia sob risco de artrite reumatoide para reduzir o desenvolvimento da artrite persistente e o impacto da doença.
2 Ago, 2022 | 13:26hIntervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial – The Lancet (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Treatment before patients develop rheumatism provides lasting relief – Leiden University Medical Centre
Comentários no Twitter:
NEW in @TheLancet—The TREAT EARLIER trial shows that initiated in patients with arthralgia at risk of #rheumatoidarthritis did not prevent the development of clinical arthritis, but did modify the disease course https://t.co/5zh7lqb4NJ pic.twitter.com/lJflW9Prwm
— The Lancet Rheumatology (@TheLancetRheum) July 22, 2022
🆕🔥Methotrexate,🇳🇱study
MTX in pre-arthritis stage➡️ did not prevent the development of clinical arthritis
but ➡️sustained improvement in
♦️MRI-detected inflammation,
♦️Symptoms (Pain & EMS)
♦️Related impairments (HAQ n Presentism)
Vs placebohttps://t.co/I0IdKydPME pic.twitter.com/cNi6AhO151— EnvisionRheumat (@ERheumat) July 29, 2022
Quando a biologia subjacente ameaça os princípios da randomização – crises de gota no início da terapia de redução do ácido úrico.
2 Ago, 2022 | 13:11hWhen underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy – Nature Reviews Rheumatology (se o acesso a este link for pago, tente este no PMC)
Comentário no Twitter
New content online! When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy https://t.co/4vBcfXXNju pic.twitter.com/BuYwypWU15
— NatRevRheumatol (@NatRevRheumatol) July 25, 2022